转移性或不可切除肿瘤免疫治疗后肺切除的安全性与可行性
本研究回顾性分析了2012至2016年间19例在免疫检查点抑制剂治疗后6个月内因疑似残留病灶接受肺切除的患者,共22次手术。结果显示R0切除率95%,并发症发生率32%(多为1/2级),2年总生存率77%、无病生存率42%。作者认为该情况下肺切除可行,但手术技术上具有挑战性。
要点
- 免疫治疗后因疑似残留病灶行肺切除,R0切除率95%,并发症发生率32%,多为1/2级。
- 2年总生存率77%,无病生存率42%,随访时间短。
- 肺切除在免疫治疗后疑似残留病灶患者中可行,但手术技术上具有挑战性。
核心结论
- 对于既往转移性或不可切除的癌症患者,免疫治疗后因疑似残留病灶行肺切除是可行的,R0切除率高。
- 手术技术上可能具有挑战性,但严重并发症似乎罕见。
- 短期随访中生存结果令人鼓舞,具有合理的生存率。
研究设计与样本
- 回顾性综述了2012年至2016年间在免疫检查点抑制剂治疗后6个月内因转移性或不可切除癌症接受肺切除的患者。
- 数据库查询确定19例患者,共接受22次因疑似残留病灶以治疗为目的的切除。
- 生存期从首次切除开始采用Kaplan-Meier法估算。
主要发现
- 最常见的诊断为肺癌(47%),其次为转移性黑色素瘤(37%)。
- 最常用的药物为纳武利尤单抗(32%)、帕博利珠单抗(32%)和伊匹木单抗(16%)。
- 患者平均接受21剂(范围1至70剂),末次给药距手术平均75天(范围7至183天)。
- 11例患者(50%)接受了解剖性切除(肺叶切除或更大范围),尝试微创肺叶切除4例,其中1例中转开胸。
- 68%的切除患者有存活肿瘤残留,R0切除率95%,肺叶切除平均手术时间227分钟(范围150至394分钟)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgeons are increasingly asked to operate on patients with residual disease after immunotherapy. The safety and utility of lung resection in this setting are unknown. METHODS: We retrospectively reviewed patients who underwent lung resection within 6 months of treatment with checkpoint blockade agents for metastatic or unresectable cancer. Survival was estimated from the first resection using the Kaplan-Meier approach. RESULTS: Database query identified 19 patients who underwent 22 resections for suspected residual disease with therapeutic intent after immunotherapy between 2012 and 2016. Lung cancer was the most common diagnosis (47%), followed by metastatic melanoma (37%). The most frequently used agents were nivolumab (32%), pembrolizumab (32%), and ipilimumab (16%). Patients received a mean of 21 doses (range, 1 to 70 doses). The final dose was administered at an average of 75 days (range, 7 to 183 days) before the operation. Anatomic resection (lobectomy or greater) was performed in 11 patients (50%). Four lobectomies were attempted minimally invasively, and one required conversion to thoracotomy. Of the resected patients, 68% had viable tumor remaining. R0 resection was achieved in 95%. Mean operative time for lobectomy was 227 minutes (range, 150 to 394 minutes). Complications occurred in 32% of patients; all but 1 were minor (grade 1/2). The 2-year overall and disease-free survival were 77% and 42%, respectively. CONCLUSIONS: In patients with previously metastatic or unresectable cancer, lung resection for suspected residual disease after immunotherapy is feasible, with high rates of R0 resection. Operations can be technically challenging, but significant morbidity appears to be rare. Outcomes are encouraging, with reasonable survivals during short-interval follow-up.
引用
- Bott MJ, Cools-Lartigue J, Tan KS, et al. Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. Ann Thorac Surg. 2018. PMID: 29550207. doi:10.1016/j.athoracsur.2018.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。